A Method to Summarize Toxicity in Cancer Randomized Clinical Trials

Area of Science:

• Oncology
• Clinical Trials
• Biostatistics

Background:

• Clinical value frameworks aim to standardize cancer trial assessments.
• A universally accepted method for summarizing trial toxicity data is lacking.
• Simplifying complex toxicity profiles is crucial for clinical decision-making.

Purpose of the Study:

• To develop a single, summary value for cancer clinical trial toxicity data, termed a weighted toxicity score (WTS).
• To explore methods for simplifying toxicity data into a quantifiable metric.
• To assess the utility of WTS in reflecting treatment tolerability.

Main Methods:

• Compiled data from 58 randomized clinical trials of FDA-approved kinase-directed inhibitors.
• Generated 5 models to assign weights to grade 1-4 toxicities.
• Calculated WTS values and correlated them with dose reduction rates as a surrogate for excessive toxicity.

Main Results:

• The clinician-weighted toxicity scale model (M5) demonstrated the strongest correlation between WTS and dose reduction rates.
• WTS differences effectively serve as a surrogate for desired dose reduction rate differences.
• The developed WTS can potentially guide dose or schedule adjustments during patient accrual.

Conclusions:

• The weighted toxicity score (WTS) successfully distills complex toxicity data into a single, interpretable value.
• WTS offers a straightforward method for integration into clinical value frameworks.
• This approach can enhance discussions regarding the risks and benefits of systemic cancer therapies.